Proteus International of the UK announced a pretax loss of L6.6 million ($10.48 million) for the year ended March 31, 1994. The result was in line with the company's expectations due to higher expenditure as product development increases, it said.
Kevin Gilmore, executive chairman at Proteus, said "modest revenues are anticipated to commence during 1994/5, to increase during 1995/6 and to provide a base for substantial expansion in 1996/7. With all programs on or ahead of schedule, I am more confident than ever of the group's progress and the potential which is now nearing fruition."
Proteus expects to see some commericalization programs come into effect in the second half of the current financial year, some of which are planned to be linked to product commercialization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze